ANL

Adlai NortyeB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$16.00

+38.2% vs current

Most likely

Base case

45%

Probability

Target price

$11.00

-5.0% vs current

B-

Bear case

30%

Probability

Target price

$6.50

-43.9% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautious-neutral. Primary-source confirmation improved the setup versus the raw packet: the company absorbed a major negative in the May 30, 2025 BURAN failure and discontinuation [#PR-2025-05-30], then recapitalized with a $140.0 million PIPE on February 3, 2026 [#PR-2026-02-03] and advanced AN9025 into Phase 1 with first-patient dosing on February 12, 2026 [#PR-2026-02-12]. That said, forward visibility is still weak because the remaining thesis depends on very early-stage assets, and some previously guided milestones from older disclosures are not yet clearly resolved in the sources checked. This remains more of a funded monitoring story than a high-conviction bullish setup.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-BURAN balance-sheet reset is largely in placeHigh impact

After discontinuing buparlisib following the failed Phase 3 BURAN readout [#PR-2025-05-30], Adlai raised approximately $140.0 million in a February 3, 2026 private placement, materially reducing immediate financing stress and allowing focus on RAS and immunotherapy assets [#PR-2026-02-03]. Near-term upside from this reset looks partly absorbed, but it lowers binary insolvency risk.

2026-07-15catalystAN4035 IND timing is a secondary pipeline optionHigh impact

The December 29, 2025 6-K said Adlai expects to submit an IND for AN4035 in the middle of 2026 [#6K-2025-12-29]. Hitting that timing would support the view that the post-BURAN company still has more than one forward program, though the value impact should stay below AN9025 until human data arrive.

2026-09-30eventAN9025 clinical execution becomes the lead proof pointHigh impact

Adlai announced first-patient dosing in the U.S. Phase 1 AN9025 study on February 12, 2026 [#PR-2026-02-12]. With AN2025 discontinued, incremental enrollment, safety, or early pharmacology updates on AN9025 are now the main stock-specific upside driver.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology